Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases.
T. Rowe Price Investment Management
Activity from announced rounds
- Rounds participated in
- 9
- Confirmed lead rounds
- 1 4 roles undisclosed
- New companies
- 8 First participation on record · 1 follow-on
- Funding in participating rounds
- $80.6B 9 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
9 in all activityLong-duration iron-air batteries designed to store electricity for multi-day grid needs.
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
Develops Claude and conducts research into reliable, interpretable and steerable artificial intelligence.
SiFive licenses RISC-V processor intellectual property for custom computing chips, including high-performance data-centre designs.
Cellares manufactures cell therapies for drug developers using automated production and quality-control systems deployed through its Smart Factory network.
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
Kardigan develops cardiovascular medicines that target specific biological drivers of heart disease and the patient groups most likely to respond.
Develops Claude and conducts research into reliable, interpretable and steerable artificial intelligence.